BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19117406)

  • 1. SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement.
    Huang SW; Li Q; Zhu SY; Li L; Xiong F; Jia YK; Xu XM
    Clin Chem Lab Med; 2009; 47(1):26-31. PubMed ID: 19117406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
    El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
    Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New allele-specific real-time PCR system for warfarin dose genotyping equipped with an automatic interpretative function that allows rapid, accurate, and user-friendly reporting in clinical laboratories.
    Kim S; Lee HW; Lee W; Um TH; Cho CR; Chun S; Min WK
    Thromb Res; 2012 Jul; 130(1):104-9. PubMed ID: 21911247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
    Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
    J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid melting curve analysis for genetic variants that underlie inter-individual variability in stable warfarin dosing.
    Carlquist JF; McKinney JT; Nicholas ZP; Clark JL; Kahn SF; Horne BD; Muhlestein JB; May HT; Anderson JL
    J Thromb Thrombolysis; 2008 Aug; 26(1):1-7. PubMed ID: 17661181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
    Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
    J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].
    Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
    Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.
    Duconge J; Cadilla CL; Windemuth A; Kocherla M; Gorowski K; Seip RL; Bogaard K; Renta JY; Piovanetti P; D'Agostino D; Santiago-Borrero PJ; Ruaño G
    Ethn Dis; 2009; 19(4):390-5. PubMed ID: 20073138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin genotyping in a single PCR reaction for microchip electrophoresis.
    Poe BL; Haverstick DM; Landers JP
    Clin Chem; 2012 Apr; 58(4):725-31. PubMed ID: 22317799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of the high resolution melting method for genotyping CYP2C9*3 (1075A/C, rs1057910) and VKORC1 (-1639A/G, rs9923231)].
    Cui GL; Ding H; Xu YJ; Chen C; Wang DW
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Jun; 40(6):477-81. PubMed ID: 22943641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
    Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC
    Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
    Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
    Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.
    Aomori T; Yamamoto K; Oguchi-Katayama A; Kawai Y; Ishidao T; Mitani Y; Kogo Y; Lezhava A; Fujita Y; Obayashi K; Nakamura K; Kohnke H; Wadelius M; Ekström L; Skogastierna C; Rane A; Kurabayashi M; Murakami M; Cizdziel PE; Hayashizaki Y; Horiuchi R
    Clin Chem; 2009 Apr; 55(4):804-12. PubMed ID: 19181737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes.
    Howard R; Leathart JB; French DJ; Krishan E; Kohnke H; Wadelius M; van Schie R; Verhoef T; Maitland-van der Zee AH; Daly AK; Barallon R
    Clin Chim Acta; 2011 Nov; 412(23-24):2063-9. PubMed ID: 21827742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.